Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose RT vs Standard CRT in High-risk LANPC Responders
NCT06092957Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Oct 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, toripalimab, adebrelimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Oct 2023; status: recruiting.
02
Drugs
camrelizumabtoripalimabadebrelimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06092957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092957.